Vertex Pharmaceuticals Incorporated re-iterated earnings guidance for the full year 2024. For the period, Company expects product revenue guidance of $10.55 to $10.75 billion.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
446.9 USD | -2.20% | +1.10% | +9.83% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.83% | 118B | |
+10.80% | 106B | |
-10.84% | 23.4B | |
-1.69% | 22.1B | |
-10.23% | 18.34B | |
-41.92% | 16.59B | |
-15.11% | 15.97B | |
+6.62% | 14.03B | |
+17.53% | 11.67B | |
-30.73% | 7.55B |
- Stock Market
- Equities
- VRTX Stock
- News Vertex Pharmaceuticals Incorporated
- Vertex Pharmaceuticals Incorporated Re-Iterates Earnings Guidance for the Full Year 2024